Nom anglais: Protein-Arginine N-Methyltransferases
Descriptor UI:D011484
Tree Number:D08.811.913.555.500.800.750
Termes MeSH sélectionnés :
Drug Development
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protein-arginine N-methyltransferases : Questions médicales les plus fréquentes",
"headline": "Protein-arginine N-methyltransferases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protein-arginine N-methyltransferases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-26",
"dateModified": "2025-03-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protein-arginine N-methyltransferases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protein Methyltransferases",
"url": "https://questionsmedicales.fr/mesh/D011496",
"about": {
"@type": "MedicalCondition",
"name": "Protein Methyltransferases",
"code": {
"@type": "MedicalCode",
"code": "D011496",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.555.500.800"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protein-arginine N-methyltransferases",
"alternateName": "Protein-Arginine N-Methyltransferases",
"code": {
"@type": "MedicalCode",
"code": "D011484",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Y George Zheng",
"url": "https://questionsmedicales.fr/author/Y%20George%20Zheng",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, United States. yzheng@uga.edu."
}
},
{
"@type": "Person",
"name": "Adam Frankel",
"url": "https://questionsmedicales.fr/author/Adam%20Frankel",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: adam.frankel@ubc.ca."
}
},
{
"@type": "Person",
"name": "Alessandra Feoli",
"url": "https://questionsmedicales.fr/author/Alessandra%20Feoli",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy."
}
},
{
"@type": "Person",
"name": "Giulia Iannelli",
"url": "https://questionsmedicales.fr/author/Giulia%20Iannelli",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy."
}
},
{
"@type": "Person",
"name": "Alessandra Cipriano",
"url": "https://questionsmedicales.fr/author/Alessandra%20Cipriano",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.",
"datePublished": "2022-11-08",
"url": "https://questionsmedicales.fr/article/36348359",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13023-022-02526-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "COSMO models for the pharmaceutical development of parenteral drug formulations.",
"datePublished": "2023-04-27",
"url": "https://questionsmedicales.fr/article/37120066",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejpb.2023.04.019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36624086",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.accounts.2c00464"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical trial considerations for pediatric cancer drug development.",
"datePublished": "2023-02-07",
"url": "https://questionsmedicales.fr/article/36749066",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/10543406.2023.2172424"
}
},
{
"@type": "ScholarlyArticle",
"name": "Changing incentives to ACCELERATE drug development for paediatric cancer.",
"datePublished": "2023-01-16",
"url": "https://questionsmedicales.fr/article/36645217",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cam4.5627"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "One-carbon group transferases",
"item": "https://questionsmedicales.fr/mesh/D019875"
},
{
"@type": "ListItem",
"position": 6,
"name": "Methyltransferases",
"item": "https://questionsmedicales.fr/mesh/D008780"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protein Methyltransferases",
"item": "https://questionsmedicales.fr/mesh/D011496"
},
{
"@type": "ListItem",
"position": 8,
"name": "Protein-arginine N-methyltransferases",
"item": "https://questionsmedicales.fr/mesh/D011484"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protein-arginine N-methyltransferases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protein-arginine N-methyltransferases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protein-arginine N-methyltransferases",
"description": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?\nQuels tests sont utilisés pour évaluer l'activité enzymatique ?\nY a-t-il des biomarqueurs associés à ces enzymes ?\nQuels symptômes peuvent indiquer un problème enzymatique ?\nComment les tests génétiques aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D011484?mesh_terms=Drug+Development&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protein-arginine N-methyltransferases",
"description": "Quels sont les symptômes d'une carence en N-méthyltransférases ?\nLes troubles de l'humeur sont-ils liés à ces enzymes ?\nPeut-on observer des symptômes neurologiques ?\nY a-t-il des symptômes spécifiques chez les enfants ?\nComment les symptômes varient-ils selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D011484?mesh_terms=Drug+Development&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protein-arginine N-methyltransferases",
"description": "Comment prévenir les troubles liés aux N-méthyltransférases ?\nY a-t-il des mesures préventives spécifiques ?\nL'éducation sur la santé est-elle importante ?\nLes vaccinations jouent-elles un rôle préventif ?\nComment le suivi médical aide-t-il à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D011484?mesh_terms=Drug+Development&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protein-arginine N-methyltransferases",
"description": "Quels traitements existent pour les dysfonctionnements enzymatiques ?\nLes médicaments peuvent-ils aider à réguler ces enzymes ?\nY a-t-il des thérapies géniques disponibles ?\nComment la nutrition influence-t-elle le traitement ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D011484?mesh_terms=Drug+Development&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protein-arginine N-methyltransferases",
"description": "Quelles complications peuvent survenir avec ces troubles ?\nLes troubles cardiovasculaires sont-ils possibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des complications à long terme ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D011484?mesh_terms=Drug+Development&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protein-arginine N-methyltransferases",
"description": "Quels sont les facteurs de risque associés ?\nL'environnement joue-t-il un rôle ?\nLe mode de vie affecte-t-il le risque ?\nLes infections peuvent-elles être un facteur de risque ?\nY a-t-il des groupes à risque spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D011484?mesh_terms=Drug+Development&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité enzymatique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques mesurent l'activité des N-méthyltransférases dans les échantillons."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à ces enzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biomarqueurs comme la méthylation de l'arginine peuvent indiquer une activité enzymatique."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème enzymatique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés comme des troubles neurologiques ou immunitaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les tests génétiques aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils identifient des mutations spécifiques dans les gènes codant pour ces enzymes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en N-méthyltransférases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, troubles cognitifs et anomalies immunitaires."
}
},
{
"@type": "Question",
"name": "Les troubles de l'humeur sont-ils liés à ces enzymes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déséquilibres peuvent affecter l'humeur et contribuer à des troubles psychiatriques."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes neurologiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques comme des convulsions peuvent être présents."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques chez les enfants ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants peuvent présenter des retards de développement et des troubles d'apprentissage."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent être plus prononcés chez les jeunes enfants et les personnes âgées."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés aux N-méthyltransférases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir ces troubles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages précoces et des conseils génétiques peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "L'éducation sur la santé est-elle importante ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sensibiliser les patients et les familles peut aider à identifier les symptômes tôt."
}
},
{
"@type": "Question",
"name": "Les vaccinations jouent-elles un rôle préventif ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui aggravent les symptômes."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet de surveiller l'état de santé et d'ajuster les traitements."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les dysfonctionnements enzymatiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des suppléments nutritionnels et des thérapies ciblées."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à réguler ces enzymes ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent moduler l'activité des N-méthyltransférases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies géniques disponibles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques pour corriger les mutations."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en nutriments peut soutenir la fonction enzymatique."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces troubles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques, immunitaires et métaboliques peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les troubles cardiovasculaires sont-ils possibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déséquilibres peuvent augmenter le risque de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des limitations fonctionnelles et des besoins de soins accrus."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications chroniques peuvent affecter la santé globale et le bien-être."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un traitement précoce et approprié."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque associés ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des carences nutritionnelles."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux comme la pollution peuvent influencer la fonction enzymatique."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire et une mauvaise alimentation augmentent le risque de troubles."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent exacerber les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque spécifiques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec des antécédents familiaux ou des troubles métaboliques sont plus à risque."
}
}
]
}
]
}
Extremely high prices facilitate drug development for ultra-rare diseases (ultra-orphan drugs). However, various problems arise in terms of healthcare financing and fairness, and the status of ultra-o...
Drug prices tended to increase as the expected number of patients to whom the drug was administered decreased; however, this trend diminished when the expected number of patients was less than 1000. O...
The status of drug prices and expected sales differed beyond a threshold of 1000 expected patients, indicating that recovering the development cost for ultra-orphan drugs is difficult. In addition, th...
The aqueous solubility of active pharmaceutical ingredients is one of the most important features to be considered during the development of parenteral formulations in the pharmaceutical industry. Com...
The outbreak of the coronavirus disease 2019 (COVID-19) pandemic and swift approval of two mRNA vaccines have put nucleic acid therapeutics in the spotlight of both the scientific community and the ge...
Oncology has been one of the most active therapeutic areas in medicinal products development. Despite this fact, few drugs have been approved for use in pediatric cancer patients when compared to the ...
More effective incentives are needed to motivate paediatric oncology drug development, uncoupling it from dependency on adult drug development. Although the current European and North-American legisla...
We propose changes in the timing and nature of the rewards within the European Paediatric Medicine Regulation (PMR) and Regulation on Orphan Medicinal Products (both currently under review), which wou...
We suggest modifying the PMR to ensure mechanism-of-action driven mandatory PIP and reorganization of incentives to a stepwise and incremental approach. Interim and final deliverables should be define...
Additionally, to address the critical gap in the current framework where there is a complete lack of incentives to promote paediatric-specific cancer drug development, we propose the introduction of e...
G-protein-coupled receptors (GPCRs) can form homodimers or heterodimers that modulate specific signal transduction pathways to regulate a wide range of physiological and pathological functions. As suc...
Diabetic retinopathy is one of the withering disorders that has been making the lives of patients miserable. Arising as a result of chronic high blood sugar levels in diabetes patients, retinopathy ha...
While the drug development literature provides numerous estimates of the financial costs to bring a new drug to market, the investment of patient-participants in the research process has not been desc...
Osteoarthritis (OA) is the most common form of arthritis worldwide, affecting ~500 million people, yet there are no effective treatments to halt its progression. Without any structure-modifying agents...